热门话题-Truist因肝病药物机遇上调Madrigal Pharma的目标价

路透中文
May 13
热门话题-Truist因肝病药物机遇上调Madrigal Pharma的目标价

5月13日 - ** Truist将Madrigal Pharmaceuticals(MDGL.O)的目标价从640美元上调至709美元,并重申“买入”评级

** 该券商表示,其医生调查显示,Madrigal Pharmaceuticals用于治疗代谢功能障碍相关脂肪性肝炎(MASH)的药物Rezdiffra具有更大的市场机遇,MASH是一种可能导致肝脏纤维化的脂肪肝疾病

** 报告称,调查显示医生更倾向于将Rezdiffra用于治疗MASH,理由是其安全性良好

** 补充称,调查还显示医生对将Rezdiffra与肠促胰素类药物(一类代谢类药物)联合使用表现出兴趣

** Truist将使用Rezdiffra治疗MASH的美国患者峰值预估从15.8万上调至19.3万

** Truist将Rezdiffra的全球峰值调整后收入预测从77亿美元上调至89亿美元

** 截至上一交易日收盘,MDGL今年以来累计下跌12.4%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10